Welcome to our dedicated page for Establishment Labs Hldgs SEC filings (Ticker: ESTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Establishment Labs Holdings Inc. (NASDAQ: ESTA) provides access to the company’s U.S. regulatory disclosures as a global medical device issuer focused on breast aesthetics and reconstruction. Through these documents, investors can review how Establishment Labs reports its financial condition, operating results, and key corporate agreements.
Core filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, where the company details revenue from its portfolio of breast health, breast aesthetics, and breast reconstruction products, as well as expenses, liquidity, and risk factors. These reports also describe its manufacturing operations in Costa Rica, quality system compliance under ISO 13485:2016 and FDA 21 CFR 820, and its intellectual property position, including patent applications and clinical evidence supporting its devices.
Current reports on Form 8-K are particularly relevant for tracking material events at Establishment Labs. Recent 8-K filings have covered earnings announcements for specific quarters and an amendment to the company’s credit agreement with Oaktree Fund Administration, LLC, including the availability of additional term loan tranches and related liquidity requirements. Such filings help clarify changes in capital structure, borrowing capacity, and other significant developments.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the content of complex filings. Users can quickly understand the implications of new 10-K and 10-Q reports, 8-K current events, and other submissions without reading every page. The platform also surfaces insider transaction disclosures on Form 4, allowing users to monitor equity transactions by Establishment Labs’ directors and officers as reported to the SEC.
ESTABLISHMENT LABS HOLDINGS INC. executive Cassandra Harris, the company’s Chief Financial Officer, has filed an initial Form 3 insider ownership report. This filing lists her as an officer but does not report any insider transactions or share movements, serving as a baseline disclosure of her status.
Establishment Labs Holdings Inc. reported that General Counsel and Chief Compliance Officer Samuel Ross Mansbach had 657 common shares withheld on March 6, 2026 to cover tax obligations tied to vesting restricted stock units. These shares were valued at $70.41 per share. After this tax-withholding disposition, he held 18,663 common shares directly.
Establishment Labs Holdings Inc. reported that its General Counsel and Chief Compliance Officer, Samuel Ross Mansbach, received equity awards on February 16, 2026. He was granted stock options for 7,131 shares at an exercise price of $0.00 and 4,082 common shares as stock units.
According to the award terms, one-fourth of the stock units and one-fourth of the option shares vest on February 16, 2027, with additional one-fourth portions vesting on each one-year anniversary thereafter. Vesting is conditioned on Mansbach continuing as a service provider through each applicable vesting date.
Establishment Labs Holdings Inc. director and Chief Executive Officer Filippo Caldini reported equity awards on February 18, 2026. He was granted 14,275 stock options with a right to buy shares at an exercise price of $0.00, along with 8,185 common shares as stock units under the 2018 Equity Incentive Plan.
According to the award terms, one-fourth of both the stock units and the option shares will vest on February 18, 2027, with the remaining portions vesting in equal annual installments on each one-year anniversary thereafter, provided he continues as a service provider through each vesting date.
Establishment Labs Holdings Inc. is a British Virgin Islands–based medical technology company focused on silicone gel-filled breast implants and related minimally invasive breast aesthetics technologies. Its Motiva Implants line, featuring SmoothSilk surfaces, ProgressiveGel, TrueMonobloc construction and RFID-based Qid/Zen, is sold in over 100 countries.
The company has expanded its U.S. presence after FDA PMA approval for Motiva Implants in September 2024 and 510(k) clearance for the Motiva Flora tissue expander in October 2023, with U.S. sales beginning in October 2024. New offerings include the Preservé tissue-preserving system launched in 2025 and the Mia Femtech minimally invasive procedure, which showed very low three-year complication and reoperation rates in a 100-patient study.
To support growth and raw-material needs, Establishment Labs entered a silicone inventory funding agreement of up to $10 million, drawing $5 million in June 2025 and $5 million in September 2025, and accessed a $25 million Tranche D term loan in September 2025. Since 2010, more than 4.8 million Motiva Implants have been sold, with approximately 7,400 complaints logged, alongside extensive ongoing IDE and post-market clinical surveillance.
Establishment Labs Holdings Inc. reported strong growth for the fourth quarter and full year 2025 and issued upbeat 2026 guidance. Fourth quarter revenue was $64.6 million, up 45.2% from 2024, while full-year revenue reached $211.1 million, a 27.2% increase.
Gross margin improved to 70.5% in the quarter. The company cut its fourth quarter net loss from operations to $3.9 million from $18.7 million, and net loss narrowed to $2.6 million. Fourth quarter adjusted EBITDA turned positive at $5.5 million versus a $13.1 million loss a year earlier.
Cash was $75.6 million as of December 31, 2025, with a note payable to Oaktree of $247.5 million and shareholders’ equity of $23.5 million. For 2026, the company guides revenue to $264–266 million, implying growth of about 25–26%, and projects revenue growth of at least 25% in 2027.
Establishment Labs Holdings Inc. files an amended Schedule 13G reporting beneficial ownership of 1,424,300 Common Shares, representing 4.9% of the class. The calculation is based on 29,057,868 Common Shares outstanding as of November 6, 2025.
The filing states that as of December 31, 2025 Mr. Juan Jose Chacon Quiros held 144,224 shares of record, had the right to acquire 151,812 shares exercisable within 60 days, and controlled 1,128,264 shares held of record by Sariel Group Ltd.
Nantahala Capital Management and its principals reported a mid‑single‑digit stake in Establishment Labs Holdings Inc. As of December 31, 2025, Nantahala and Wilmot B. Harkey each may be deemed to beneficially own 987,689 common shares, or about 3.40% of outstanding shares, while Daniel Mack is reported at 3.50%, including 28,218 shares he controls solely. The securities are described as held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Brown Advisory Inc and related entities reported beneficial ownership of 2,038,652 Establishment Labs Holdings Inc. common shares, representing 7.02% of the class as of 12/31/2025.
Most voting power sits with Brown Advisory Inc and Brown Advisory LLC, while dispositive power is largely shared across subsidiaries. The shares are beneficially owned by investment companies and other managed accounts of Brown Advisory’s subsidiaries. The group certifies the holdings are in the ordinary course of business and not intended to change or influence control of Establishment Labs.
Establishment Labs Holdings Inc. filed a Form 8-K to share that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026. The company is furnishing, rather than filing, the investor presentation as Exhibit 99.1, meaning it is not subject to certain liability provisions that apply to filed information.
The report highlights that the materials may contain forward-looking statements and preliminary financial data prepared by management. The company notes that its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, or provided any assurance on this preliminary financial information, so it should not be relied on as a substitute for full GAAP financial statements.